Next Article in Journal
An Estimation of Radiobiological Parameters for Head-and-Neck Cancer Cells and the Clinical Implications
Next Article in Special Issue
The Expression of Embryonic Liver Development Genes in Hepatitis C Induced Cirrhosis and Hepatocellular Carcinoma
Previous Article in Journal
The Stroma—A Key Regulator in Prostate Function and Malignancy
Previous Article in Special Issue
A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase
Article Menu

Export Article

Open AccessReview
Cancers 2012, 4(2), 549-565; doi:10.3390/cancers4020549

Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials

1
Clinical Trials Unit, National Cancer Institute—“G. Pascale” Foundation, via Mariano Semmola, Napoli 80131, Italy
2
Medical Statistics, Second University, v. L. Armanni 5, Napoli 80138, Italy
3
Medical Oncology Unit, “G.Rummo” Hospital, Benevento 82100, Italy
*
Author to whom correspondence should be addressed.
Received: 8 May 2012 / Revised: 25 May 2012 / Accepted: 30 May 2012 / Published: 5 June 2012
(This article belongs to the Special Issue Advances and Research Progress in Hepatocellular Carcinoma)
View Full-Text   |   Download PDF [163 KB, uploaded 5 June 2012]   |  

Abstract

No systemic therapy had been proven effective in patients with advanced hepatocellular carcinoma (HCC) until 2007, when a large randomized trial with sorafenib demonstrated a clinically relevant prolongation of survival. Currently, sorafenib represents standard treatment for patients with advanced HCC and well-preserved liver function, whilst the evidence about its effectiveness in patients with more severe liver impairment is less robust. A randomized trial to demonstrate the efficacy of sorafenib in Child-Pugh B patients with advanced HCC is currently ongoing. In the meantime, several trials are testing the role of sorafenib in early HCC (as adjuvant treatment after potentially curative loco-regional therapies) and in intermediate stage (exploring different modalities of integration of sorafenib with trans-arterial chemo-embolization). The results of all these trials will better define the potentiality and the boundaries of use of sorafenib in HCC patients. View Full-Text
Keywords: hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization hepatocellular carcinoma; sorafenib; Child-Pugh B patients; trans-arterial chemo-embolization
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Di Maio, M.; Daniele, G.; Piccirillo, M.C.; Giordano, P.; Signoriello, G.; Daniele, B.; Perrone, F. Potentiality and Boundaries of Use of Sorafenib in Patients with Hepatocellular Carcinoma: Awaiting the Results of Ongoing Clinical Trials. Cancers 2012, 4, 549-565.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top